Norway· NO-ID_F3D3E8E7-A7E6-4F39-AF83-AB89D0AD635F
Benlysta
A belimumab product containing belimumab, registered in Norway by GlaxoSmithKline (Ireland) Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Belimumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG04 (belimumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Belimumab · ATC L04AG04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belimumab costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Belimumab · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$45.43
The record
At a glance
FEST (Norway)- Active substance
- Belimumab
- Manufacturer
- GlaxoSmithKline (Ireland) Limited
- Country
- Norway (NO)
- ATC code
- L04AG04
- ATC class
- Belimumab
- Defined daily dose
- 25 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_F3D3E8E7-A7E6-4F39-AF83-AB89D0AD635F
- no_varenummer0539614 x 1NOK 11647.9
- gtin5054290000443
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for belimumab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Belimumab · interactions on record
61 records
- 28 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Belimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBENLYSTAGlaxoSmithKline (Ireland) Limited, Dublin
- BelgiumBenlysta 200 mgGlaxoSmithKline
- IcelandBenlystaGlaxoSmithKline (Ireland) Limited
- SwedenBenlysta 200 mg Injektionsvätska, lösning i förfylld injektionspennaGlaxoSmithKline (Ireland) Limited
- SpainBENLYSTA 200 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAGlaxosmithkline (Ireland) Limited
- United KingdomBenlysta 200mg/1ml solution for injection pre-filled pensGlaxoSmithKline UK Ltd
- FinlandBenlystaOrifarm Oy
- United StatesBENLYSTAGlaxoSmithKline LLC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Benlysta
- Liechtenstein · Benlysta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a42505ff-adc8-4443-bc87-35223d6610cf GET /v1/drugs/a42505ff-adc8-4443-bc87-35223d6610cf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Belimumab",
"merkevare_id": "ID_F3D3E8E7-A7E6-4F39-AF83-AB89D0AD635F",
"name_form_strength": "Benlysta inj, oppl 200 mg/penn",
"prescription_group": "C"
}See everything about belimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.